Sign In
Buy TWST
$91.55
+0.220 (+0.241%)
At Close: Jul 31, 2026
Twist Bioscience Spins Out DNA Data Storage as Independent Company
07:10am, Monday, 05'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers
12:05pm, Thursday, 01'st May 2025
Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, Twis
Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System
08:00am, Thursday, 24'th Apr 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System.
Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics
08:00am, Monday, 31'st Mar 2025
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
10:41am, Friday, 28'th Mar 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
01:15pm, Wednesday, 12'th Mar 2025
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
07:30am, Tuesday, 11'th Mar 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know
01:00pm, Thursday, 06'th Feb 2025
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cathie Wood dumped Palantir to buy these biotech stocks
08:42am, Thursday, 06'th Feb 2025
Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure.
Twist Bioscience: Valuation Is Weighing On The Stock
11:30pm, Wednesday, 05'th Feb 2025
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
10:55am, Monday, 03'rd Feb 2025
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates
09:25am, Monday, 03'rd Feb 2025
Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago.
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
07:15am, Monday, 03'rd Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research
10:35am, Thursday, 23'rd Jan 2025
The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% duri
All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy
01:00pm, Friday, 27'th Dec 2024
Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
